CLINICAL TRIALS PROFILE FOR TRELSTAR
✉ Email this page to a colleague
All Clinical Trials for TRELSTAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01467882 ↗ | Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | Completed | Debiopharm International SA | Phase 3 | 2012-04-01 | The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks). |
| NCT02090114 ↗ | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2014-06-01 | Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20). |
| NCT02090114 ↗ | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | Recruiting | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2014-06-01 | Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20). |
| NCT02090114 ↗ | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 2014-06-01 | Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRELSTAR
Condition Name
Clinical Trial Locations for TRELSTAR
Trials by Country
Clinical Trial Progress for TRELSTAR
Clinical Trial Phase
Clinical Trial Sponsors for TRELSTAR
Sponsor Name
